| Schedule of restatement |
| | As Previously Reported | | | Adjustment | | | As Restated | | As of December 31, 2025 | | | | | | | | | | Consolidated Balance Sheet | | | | | | | | | | Series A Preferred Stock | | $ | 1,200 | | | $ | (800 | ) | | $ | 500 | | Additional paid in capital | | $ | 3,465,466 | | | $ | 39,700 | | | $ | 3,505,166 | | Accumulated deficit | | $ | (4,229,711 | ) | | $ | (39,000 | ) | | $ | (4,268,711 | ) | Total Stockholders' Equity | | $ | 757,517 | | | $ | - | | | $ | 757,517 | | | | | | | | | | | | | | | For the year ended December 31, 2025 | | | | | | | | | | | | | Statement of Operations: | | | | | | | | | | | | | | | | | | | | | | | | | | Professional fees | | $ | 74,949 | | | $ | 39,000 | | | $ | 113,949 | | Loss from operations | | $ | (280,232 | ) | | $ | (39,000 | ) | | $ | (319,232 | ) | Net loss | | $ | (264,354 | ) | | $ | (39,000 | ) | | $ | (303,354 | ) |
|